INVA
Innoviva, Inc. NASDAQ$22.99
Mkt Cap $1.5B
52w Low $16.52
75.0% of range
52w High $25.15
50d MA $23.01
200d MA $20.58
P/E (TTM)
5.8x
EV/EBITDA
2.8x
P/B
1.3x
Debt/Equity
0.2x
ROE
23.1%
P/FCF
6.9x
RSI (14)
—
ATR (14)
—
Beta
0.40
50d MA
$23.01
200d MA
$20.58
Avg Volume
764.4K
About
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidiniu…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 25, 2026 | AMC | 0.34 | 1.94 | +470.6% | 24.24 | +3.1% | -2.9% | -5.3% | -5.8% | -8.0% | -6.2% | -6.5% | — |
| Nov 5, 2025 | AMC | 0.46 | 1.08 | +134.8% | 18.23 | +8.9% | +12.9% | +14.4% | +14.5% | +20.1% | +22.2% | +13.8% | — |
| Aug 6, 2025 | AMC | 0.57 | 0.77 | +35.1% | 18.25 | +0.1% | +1.2% | +0.5% | +7.7% | +10.1% | +12.9% | +12.2% | — |
| May 7, 2025 | AMC | 0.29 | 0.25 | -13.8% | 18.74 | +0.1% | -0.9% | -1.0% | -0.7% | -2.6% | -3.9% | +15.2% | — |
| Feb 26, 2025 | AMC | 0.34 | 0.57 | +67.6% | 17.90 | +0.8% | -2.0% | +0.1% | -0.6% | -1.8% | -1.6% | +1.6% | — |
| Nov 6, 2024 | AMC | 0.27 | 0.02 | -92.6% | 19.92 | -0.2% | +0.4% | +1.3% | +1.0% | +2.0% | +0.9% | -4.4% | — |
| Jul 31, 2024 | AMC | 0.24 | 0.68 | +183.3% | 18.84 | -4.4% | +2.4% | +1.3% | -2.8% | -2.5% | -3.7% | +2.9% | — |
| May 8, 2024 | AMC | 0.17 | 0.46 | +170.6% | 15.56 | +0.6% | -1.7% | +0.3% | +4.0% | +3.5% | +1.8% | +3.7% | — |
| Feb 29, 2024 | AMC | 0.23 | 0.76 | +230.4% | 15.28 | +9.0% | -0.3% | -0.1% | -2.6% | -0.7% | -1.3% | -0.5% | — |
| Nov 1, 2023 | AMC | 0.27 | 0.98 | +263.0% | 12.42 | +6.6% | +6.9% | +9.7% | +9.9% | +10.2% | +10.8% | +12.6% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26 | BTIG | Maintains | Buy → Buy | — | $24.24 | $25.00 | +3.1% | -2.9% | -5.3% | -5.8% | -8.0% | -6.2% |
| Dec 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.14 | $20.71 | +2.8% | -1.1% | -0.4% | -0.3% | -0.7% | -0.7% |
| Nov 6 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $18.23 | $19.85 | +8.9% | +12.9% | +14.4% | +14.5% | +20.1% | +22.2% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.34 | $18.96 | +3.4% | +7.1% | +9.5% | +12.4% | +13.8% | +14.1% |
| May 10 | EF Hutton | Maintains | Buy → Buy | — | $11.56 | $11.76 | +1.7% | +5.5% | +7.5% | +9.6% | +11.7% | +14.6% |
| Apr 20 | EF Hutton | Maintains | Buy → Buy | — | $11.85 | $11.85 | +0.0% | -0.1% | +1.1% | -0.4% | -1.0% | +0.2% |
| Mar 3 | EF Hutton | Maintains | Buy → Buy | — | $10.93 | $10.93 | +0.0% | +0.5% | +0.8% | -0.4% | +0.3% | -1.8% |
| Mar 3 | Goldman Sachs | Maintains | Neutral → Neutral | — | $10.93 | $10.93 | +0.0% | +0.5% | +0.8% | -0.4% | +0.3% | -1.8% |
| Mar 3 | Morgan Stanley | Maintains | Underweight → Underweight | — | $10.93 | $10.93 | +0.0% | +0.5% | +0.8% | -0.4% | +0.3% | -1.8% |
| Jan 24 | Morgan Stanley | Maintains | Underweight → Underweight | — | $12.94 | $12.73 | -1.6% | -3.9% | -4.0% | -2.0% | -1.9% | -3.6% |
Recent Filings
Data updated apr 25, 2026 3:54pm
· Source: massive.com